Drug Research, Table of Contents Drug Res (Stuttg) 2021; 71(S 01): S26-S27DOI: 10.1055/a-1606-5983 Extended Abstract Zellmigration als therapeutischer Zielprozess Authors Sebastian Zundler Recommend Article Abstract Full Text References Literatur 1 Sandborn WJ, Feagan BG, Rutgeerts P. et al. Vedolizumab as induction and maintenance therapy for Crohnʼs disease. N Engl J Med 2013; 369: 711-721 2 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 3 Zundler S, Becker E, Schulze LL. et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019; 68: 1688-1700 4 Iwata M, Hirakiyama A, Eshima Y. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-538 5 Zundler S, Becker E, Spocinska M. et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat Immunol 2019; 20: 288-300 6 William S, Geert D, Doug W. et al. P025 ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North Study. Official journal of the American College of Gastroenterology | ACG 2020; 115: S6 7 Watanabe M, Matsuoka K, Ohmori T. et al. OP34 AJM300, an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled induction study. Journal of Crohnʼs and Colitis 2021; 15: S031-S032 8 Kim SV, Xiang WV, Kwak C. et al. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science 2013; 340: 1456-1459 9 Otto O, Rosendahl P, Mietke A. et al. Real-time deformability cytometry: on-the-fly cell mechanical phenotyping. Nat Methods 2015; 12: 199-202 4 p following 202
